Australian Clinical Labs Limited
ASX: ACL.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Melinda McGrath
- Employees
- 4,900
- Headquarters
- Clayton, Australia
- IPO year
- 2021
- Market cap
- A$360.3M
- Website
- https://www.clinicallabs.com.au
Loading ACL…
Loading profile data…Frequently asked questions about ACL
What does Australian Clinical Labs Limited (ACL.AX) do?
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunolo...
Where does ACL.AX trade?
Australian Clinical Labs Limited (ACL.AX) trades on the Australian Securities Exchange.
What sector is ACL.AX in?
Australian Clinical Labs Limited (ACL.AX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Australian Clinical Labs Limited?
Melinda McGrath is the chief executive officer of Australian Clinical Labs Limited (ACL.AX).
Where is Australian Clinical Labs Limited headquartered?
Australian Clinical Labs Limited is headquartered in Australia.
Does ACL.AX pay a dividend?
Yes — Australian Clinical Labs Limited (ACL.AX) paid a trailing twelve-month dividend of AUD 0.13 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ACL.AX go public?
Australian Clinical Labs Limited (ACL.AX) completed its initial public offering in 2021.